US24823R1059
US24823R1059
Denali Therapeutics Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 555.342.000 | 501.878.000 | 10.7% | |
| Operating Income | -555.342.000 | -501.878.000 | 10.7% |
| Pretax Income | -512.438.000 | -422.705.000 | 21.2% |
| Net Income Common Stockholders | -512.540.000 | -422.773.000 | 21.2% |
| -- | -- | -- | |
| -- | -- | -- |